Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.22.2.2
Commitments and Contingencies (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Sep. 30, 2021
USD ($)
payment
Feb. 03, 2020
USD ($)
milestone
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
milestone
therapy
Sep. 30, 2022
USD ($)
payment
Sep. 30, 2021
USD ($)
payment
Jun. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
payment
Sep. 30, 2021
USD ($)
payment
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Operating Leased Assets [Line Items]                                
Selling, general and administrative         $ 3,284 $ 5,926   $ 17,752 $ 18,677              
Payment received     $ 2,000                          
Period after public launch to terminate agreement     3 years                          
Percentage of net present value of royalty payments     75.00%                          
Aevi                                
Operating Leased Assets [Line Items]                                
Milestone payment               0                
Aevi                                
Operating Leased Assets [Line Items]                                
Number of milestones | milestone   2                            
Contingent consideration   $ 6,500                            
Ichorion                                
Operating Leased Assets [Line Items]                                
Number of milestones | milestone       3                        
Contingent consideration       $ 15,000                        
Milestone payment               0                
AVTX-801, AVTX-802, And AVTX-803 | Ichorion                                
Operating Leased Assets [Line Items]                                
Number of preclinical therapies | therapy       3                        
AVTX-913 | Ichorion                                
Operating Leased Assets [Line Items]                                
Number of preclinical therapies | therapy       1                        
Milestone One | Aevi                                
Operating Leased Assets [Line Items]                                
Contingent consideration   2,000                            
Milestone One | Ichorion                                
Operating Leased Assets [Line Items]                                
Milestone payment                     $ 6,000          
Milestone Two | Aevi                                
Operating Leased Assets [Line Items]                                
Contingent consideration   $ 4,500                            
Milestone Two | Ichorion | Forecast                                
Operating Leased Assets [Line Items]                                
Milestone payment                       $ 5,000        
Milestone Three | Ichorion                                
Operating Leased Assets [Line Items]                                
Milestone payment               0                
Milestone Three | Ichorion | Forecast                                
Operating Leased Assets [Line Items]                                
Milestone payment                       $ 4,000        
Alto | AVTX-301 Out-License                                
Operating Leased Assets [Line Items]                                
Maximum proceeds from milestones                             $ 18,600  
Revenue recognized from milestones to date         0     0                
ES | AVTX-406 License Assignment                                
Operating Leased Assets [Line Items]                                
Revenue recognized from milestones to date         0     0                
ES | Milestone One | AVTX-406 License Assignment                                
Operating Leased Assets [Line Items]                                
Maximum proceeds from milestones                           $ 6,000    
ES | Milestone Two | AVTX-406 License Assignment                                
Operating Leased Assets [Line Items]                                
Maximum proceeds from milestones                           $ 20,000    
Karbinal Agreement | TRIS Pharma                                
Operating Leased Assets [Line Items]                                
Minimum quantity required | unit                   70,000            
Make whole payment per unit (in dollars per share) | $ / shares                   $ 30            
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC)                                
Operating Leased Assets [Line Items]                                
Upfront license fee                               $ 10,000
Percent of payments received from sublicensing                               30.00%
Research and development expense               0 10,000              
Cumulative expense recognized to date         0     0                
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone One                                
Operating Leased Assets [Line Items]                                
Maximum aggregate milestone payment                               $ 112,500
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone Two                                
Operating Leased Assets [Line Items]                                
Maximum aggregate milestone payment                               $ 75,000
AVTX-006 Astellas License Agreement | Astellas Pharma, Inc. (Astellas)                                
Operating Leased Assets [Line Items]                                
Upfront license fee         500     500                
Maximum aggregate milestone payment         5,500     5,500                
Research and development expense               0                
Cumulative expense recognized to date         500     500                
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute                                
Operating Leased Assets [Line Items]                                
Upfront license fee                         $ 400      
Research and development expense           400   0 400              
Cumulative expense recognized to date         $ 0     $ 0                
Patent costs                         500      
Selling, general and administrative           500     500              
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone One                                
Operating Leased Assets [Line Items]                                
Maximum aggregate milestone payment                         24,200      
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone Two                                
Operating Leased Assets [Line Items]                                
Maximum aggregate milestone payment                         $ 50,000      
Deerfield Obligation | AYTU                                
Operating Leased Assets [Line Items]                                
Maximum potential future payments $ 3,000         $ 3,000     $ 3,000              
Number of quarterly payments | payment 6       1 6   1 6              
Periodic payment $ 500           $ 1,000